Market Overview

Gilead Announces Phase 2 Study Results for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma at ASH


Gilead Sciences (Nasdaq: GILD) today announced results of a Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. In this study, single-agent treatment with idelalisib achieved an overall response rate of 57 percent with a median duration of response of 12.5 months. The data were presented today during an oral session at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans. #ASH13

See full press release

Posted-In: News Guidance Management Events Global


Related Articles (GILD)

View Comments and Join the Discussion!

Nuverra Responds to Texas Jury Award of $181M Against Subsidiary Heckmann Water Resources

Benzinga's Weekend M&A Chatter